|
| 37040116 | Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial. | JAMA Netw Open | 2023 |
| 34561270 | Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. | Clin Cancer Res | 2022 |
| 35544137 | Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial. | JAMA Netw Open | 2022 |
| 35598024 | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. | Alzheimers Res Ther | 2022 |
| 35815677 | PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. | Leuk Lymphoma | 2022 |
| 35623341 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. | Cancer Cell | 2022 |
| 36400018 | Evaluation of cell-free DNA approaches for multi-cancer early detection. | Cancer Cell | 2022 |
| 36456573 | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. | NPJ Breast Cancer | 2022 |
| 36482412 | Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. | Alzheimers Res Ther | 2022 |
| 35993547 | The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. | Clin Trials | 2022 |
| 36302890 | Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. | NPJ Precis Oncol | 2022 |
| 36261575 | Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. | Leukemia | 2022 |
| 34890069 | A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. | Muscle Nerve | 2022 |
| 33293373 | Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. | Clin Cancer Res | 2021 |
| 33742104 | Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. | NPJ Precis Oncol | 2021 |
| 33617937 | Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. | Ann Oncol | 2021 |
| 33865446 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. | Alzheimers Res Ther | 2021 |
| 34529930 | Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. | Lancet Oncol | 2021 |
| 34529000 | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34611148 | Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. | NPJ Breast Cancer | 2021 |
| 34427465 | Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. | Radiology | 2021 |
| 34741023 | Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial. | Nat Commun | 2021 |
| 34329317 | Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. | PLoS One | 2021 |
| 34215688 | Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. | J Immunother Cancer | 2021 |
| 34146566 | Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis. | Gastroenterology | 2021 |
| 34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Cancer Cell | 2021 |
| 33188142 | Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. | Clin Cancer Res | 2021 |
| 32552276 | Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. | J Clin Oncol | 2020 |
| 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | J Clin Oncol | 2020 |
| 32053137 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. | JAMA Oncol | 2020 |
| 33030517 | Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. | JAMA Oncol | 2020 |
| 33362278 | A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. | PLoS One | 2020 |
| 33298938 | Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. | NPJ Breast Cancer | 2020 |
| 33095682 | Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. | J Clin Oncol | 2020 |
| 32790733 | Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. | PLoS One | 2020 |
| 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32391579 | A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. | Int J Cancer | 2020 |
| 31339827 | Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. | J Clin Oncol | 2019 |
| 29808479 | A nonparametric Bayesian basket trial design. | Biom J | 2019 |
| 28627297 | A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. | Med Decis Making | 2018 |
| 32914002 | Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. | JCO Precis Oncol | 2018 |
| 30239794 | Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. | J Natl Cancer Inst | 2018 |
| 30046830 | Concern Regarding Age Distribution of Breast Cancer. | JAMA Surg | 2018 |
| 30037817 | Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. | Clin Cancer Res | 2018 |
| 29896623 | Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply. | JAMA | 2018 |
| 30268698 | Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. | J Thorac Oncol | 2018 |
| 29554472 | Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. | Med Decis Making | 2018 |
| 29572535 | Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. | Nat Commun | 2018 |
| 29718314 | Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. | J Natl Cancer Inst | 2018 |
| 29765547 | Signature program: a platform of basket trials. | Oncotarget | 2018 |